MA51644A - Méthodes d'évaluation de la capacité de transduction de vecteurs viraux - Google Patents

Méthodes d'évaluation de la capacité de transduction de vecteurs viraux

Info

Publication number
MA51644A
MA51644A MA051644A MA51644A MA51644A MA 51644 A MA51644 A MA 51644A MA 051644 A MA051644 A MA 051644A MA 51644 A MA51644 A MA 51644A MA 51644 A MA51644 A MA 51644A
Authority
MA
Morocco
Prior art keywords
evaluating
methods
viral vectors
transduction capacity
transduction
Prior art date
Application number
MA051644A
Other languages
English (en)
Inventor
Agathe Bourgogne
Mamta Kalra
Ali Mohamed
Steffen Walter
Original Assignee
Immatics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Us Inc filed Critical Immatics Us Inc
Publication of MA51644A publication Critical patent/MA51644A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
MA051644A 2018-01-17 2019-01-17 Méthodes d'évaluation de la capacité de transduction de vecteurs viraux MA51644A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862618295P 2018-01-17 2018-01-17
DE102018100967.4A DE102018100967B4 (de) 2018-01-17 2018-01-17 Verfahren zur feststellung der wirksamkeit von viralen vektoren

Publications (1)

Publication Number Publication Date
MA51644A true MA51644A (fr) 2020-11-25

Family

ID=67068579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051644A MA51644A (fr) 2018-01-17 2019-01-17 Méthodes d'évaluation de la capacité de transduction de vecteurs viraux

Country Status (13)

Country Link
US (2) US20190216852A1 (fr)
EP (1) EP3740216B1 (fr)
CN (1) CN111936153A (fr)
CA (1) CA3088165A1 (fr)
DE (1) DE102018100967B4 (fr)
DK (1) DK3740216T3 (fr)
ES (1) ES2916048T3 (fr)
HU (1) HUE058665T2 (fr)
MA (1) MA51644A (fr)
PL (1) PL3740216T3 (fr)
SG (1) SG11202006498PA (fr)
TW (1) TW201934755A (fr)
WO (1) WO2019143772A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
CN114303060A (zh) 2019-06-06 2022-04-08 伊玛提克斯生物技术有限公司 使用序列相似肽进行反向选择分选
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CN112183433B (zh) * 2020-10-12 2024-02-23 水木未来(北京)科技有限公司 一种实心和空心病毒颗粒的表征量化方法
WO2022147029A2 (fr) 2020-12-31 2022-07-07 Immatics US, Inc. Polypeptides cd8, compositions et leurs méthodes d'utilisation
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
WO2022184805A1 (fr) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant spécifiquement à des peptides antigéniques du sars-cov-2 en un complexe avec une protéine du complexe majeur d'histocompatibilité
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス，アイエヌシー． 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514834A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides récepteurs de tgfbêta négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
EP4514821A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
WO2023215825A1 (fr) 2022-05-05 2023-11-09 Immatics US, Inc. Procédés d'amélioration de l'efficacité d'un lymphocyte t
WO2025096649A1 (fr) 2023-11-01 2025-05-08 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US6248514B1 (en) 1996-07-09 2001-06-19 Canji, Inc. Methods for measuring viral infectivity
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
BRPI0607540B1 (pt) 2005-04-13 2017-05-09 Merial Ltd ensaio para a produção de circovírus porcino
CA2703045C (fr) 2007-10-25 2017-02-14 Sangamo Biosciences, Inc. Procedes et compositions pour une integration ciblee
US10982189B2 (en) 2014-07-11 2021-04-20 Celgene Corporation Methods of improving vector transduction efficiency into T lymphocytes
ES2837133T3 (es) 2015-07-24 2021-06-29 Boehringer Ingelheim Animal Health Usa Inc Procedimiento de cuantificación de virus de alto rendimiento

Also Published As

Publication number Publication date
DE102018100967A1 (de) 2019-07-18
PL3740216T3 (pl) 2022-06-13
ES2916048T3 (es) 2022-06-28
US20250034588A1 (en) 2025-01-30
CA3088165A1 (fr) 2019-07-25
SG11202006498PA (en) 2020-08-28
US20190216852A1 (en) 2019-07-18
TW201934755A (zh) 2019-09-01
CN111936153A (zh) 2020-11-13
WO2019143772A1 (fr) 2019-07-25
HUE058665T2 (hu) 2022-09-28
DE102018100967B4 (de) 2019-08-14
EP3740216A1 (fr) 2020-11-25
DK3740216T3 (da) 2022-05-23
EP3740216B1 (fr) 2022-03-02

Similar Documents

Publication Publication Date Title
MA51644A (fr) Méthodes d'évaluation de la capacité de transduction de vecteurs viraux
EP4049466A4 (fr) Estimation d'empreinte de réverbération
EP3942754A4 (fr) Routage de pondération
EP3890786A4 (fr) Vecteur viral adéno-associé recombiné pour l'insertion de gènes
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l'adn
EP3749346A4 (fr) Domaines variables d'anticorps ciblant le récepteur nkg2d
EP3898997A4 (fr) Vecteurs d'orthopoxvirus modifiés
IL282885A (en) Aav viral vectors and uses thereof
EP3860449A4 (fr) Agencement d'électrodes
MA51915A (fr) Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna)
EP3735466A4 (fr) Vecteurs d'orthopoxvirus modifiés
EP3701926C0 (fr) Système de suspension amélioré
EP3893931A4 (fr) Méthodes d'utilisation d'anticorps anti-trem2
EP3815941A4 (fr) Suspension
DK3725097T3 (da) Fordelte transducerophængspoler (dtsc)
EP3723657A4 (fr) Nettoyage à l'aide de suspension
EP3917832A4 (fr) Amortisseur d'avance-recul
EP3746058A4 (fr) Compositions et méthodes d'amélioration de la biodisponibilité de 5-hydroxytryptophane
EP4330413A4 (fr) Vecteurs viraux adéno-associés pour la transduction de la cochlée
IL281083A (en) Adeno-associated viral vectors for the treatment of best disease
EP3496882A4 (fr) Plaque d'amortissement
FR3051693B1 (fr) Reseau d'elements transducteurs ultrasonores
EP3833084A4 (fr) Configuration d'instance openflow
EP3897902A4 (fr) Séparation d'oligosaccharides
EP4021442A4 (fr) Inhibiteurs conjugués de la réponse à l'endommagement de l'adn